Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
STI571 (Gleevec™) as a paradigm for cancer therapy
Brian J. Druker
Knight Cancer Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
260
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'STI571 (Gleevec™) as a paradigm for cancer therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Imatinib Mesylate
100%
Neoplasms
28%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18%
Patient Selection
15%
Therapeutics
14%
Clinical Trials
11%